Mechanisms of resistance to immune checkpoint inhibitors and strategies to reverse drug resistance in lung cancer / 中华医学杂志(英文版)
Chinese Medical Journal
;
(24): 2444-2455, 2020.
Article
in English
| WPRIM
| ID: wpr-877859
ABSTRACT
In recent years, the research of immune checkpoint inhibitors has made a great breakthrough in lung cancer treatment. Currently, a variety of immune checkpoint inhibitors have been applied into clinical practice, including antibodies targeting the programmed cell death-1, programmed cell death-ligand 1, and cytotoxic T-lymphocyte antigen 4, and so on. However, not all patients can benefit from the treatment. Abnormal antigen presentation, functional gene mutation, tumor microenvironment, and other factors can lead to primary or secondary resistance. In this paper, we reviewed the molecular mechanism of immune checkpoint inhibitor resistance and various combination strategies to overcome resistance, in order to expand the beneficial population and enable precision medicine.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Drug Resistance
/
Tumor Microenvironment
/
B7-H1 Antigen
/
CTLA-4 Antigen
/
Immune Checkpoint Inhibitors
/
Immunotherapy
/
Lung Neoplasms
Limits:
Humans
Language:
English
Journal:
Chinese Medical Journal
Year:
2020
Type:
Article
Similar
MEDLINE
...
LILACS
LIS